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Providers should remain cautious while 
prescribing high doses of 
bisphosphonates in patients with 
increased risk factors to prevent, timely 
diagnose and treat this condition. 
First described in 2002, osteonecrosis of 
the jaw (ONJ, or avascular necrosis of the 
jaw) is an uncommon but potentially 
serious side eﬀect of treatment with 
bisphosphonates. Although 
typically identified in patients with 
multiple myeloma and other 
malignancies, a few cases have been 
reported in patients taking 
bisphosphonates - a potent drug class 
used in the treatment of osteoclast-
mediated bone resorption issues, 
including postmenopausal osteoporosis, 
Paget's disease, multiple myeloma, and 
malignant hypercalcemia. The clinical 
diagnosis of ONJ can be obscured by 
jaw pain, abscess, swelling, and fistulas, 
but exposed bone is a distinctive 
sign. This reports a case of ONJ 
secondary to bisphosphonate use in a 
65-year-old woman and clinical 
management complications.
ONJ, often associated with pain, 
swelling, exposed bone, local infection, 
and pathologic fracture of the jaw, is a 
rare complication of bisphosphonate 
therapy. Currently, no prospective data 
exists to advise the benefits of therapy 
discontinuation however most clinical 
practices tend to discontinue at least 
temporarily.  The incidence increases 
with longer treatment duration, 
particularly when therapy exceeds four 
years. Risk factors for developing ONJ 
while taking bisphosphonates include IV 
administration, anticancer therapy, dose 
and duration of exposure, dental 
extractions/implants, glucocorticoids, 
smoking, diabetes, and preexisting dental 
disease. 

Case presentation continued Discussion continued
Later, patient complained of a piece of 
bone penetrating the skin of her chin and 
presented with continuous drainage from 
sinus tract in her mandible, which was 
diagnosed as osteonecrosis attributed to 
bisphosphonates, previous radiation 
therapy, and dental abscesses. 

Patient was started on abaloparatide, an 
osteo-anabolic medication for 
osteoporosis and enrolled in hyperbaric 
oxygen therapy which immensely helped 
in controlling sinus drainage. Patient is 
currently awaiting mandibular 
reconstruction surgery.
Case reports and series suggest benefit 
from hyperbaric oxygen therapy in wound 
healing, pain, and quality of life at three 
months, however no significant 
diﬀerences exist with outcomes beyond 
three months. Patients being considered 
for therapy with a bisphosphonate should 
be thoroughly evaluated for dental issues, 
prior to initiating therapy. Conservative 
management with limited debridement, 
antibiotic therapy as needed, and topical 
mouth rinses rather than aggressive 
surgical resection are recommended. 
Conservative therapy may result in 
healing in a significant proportion of 
patients. Surgical resection of necrotic 
bone should be reserved for refractory or 
advanced cases.
A 65-year-old lady with history of age-
related osteoporosis and compression 
fractures on alendronate for 4 
years, squamous cell carcinoma of neck 
status post excision and radiotherapy 11-
years prior, Sjogren's syndrome and 
discoid lupus on hydroxychloroquine, 
diabetes, hypertension, stroke and 
multiple dental abscesses presents with 
persistent neck pain. Initial CT neck with 
contrast showed diﬀuse fat stranding. 
Subsequently, alendronate was 
discontinued due to jaw necrosis 
suspicion. Eight months later, repeat CT 
scan showed new non-mass-like soft 
tissue thickening in the subcutaneous fat 
abutting the right anterior mandible 
with mandibular teeth cavities and 
periapical lucencies, likely to be 
periodontal cellulitis 
versus radiation osteonecrosis. 
Osteonecrosis of Right Mandible showing 
eroded bone and bone within bone formation 
secondary to bisphosphonate use and radiation 
treatment.
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